Association of serum 25-hydroxyvitamin D with the incidence of 16 cancers, cancer mortality, and all-cause mortality among individuals with metabolic syndrome: a prospective cohort study
- PMID: 37209191
- DOI: 10.1007/s00394-023-03169-x
Association of serum 25-hydroxyvitamin D with the incidence of 16 cancers, cancer mortality, and all-cause mortality among individuals with metabolic syndrome: a prospective cohort study
Abstract
Purpose: The relationship between vitamin D levels and cancer incidence and mortality in individuals with metabolic syndrome (MetS) remains poorly explored. Herein, we aimed to determine the association between 25-hydroxyvitamin D [25(OH)D] concentrations and the risk of 16 cancer incidence types and cancer/all-cause mortality in patients with MetS.
Methods: We enrolled 97,621 participants with MetS at recruitment from the UK Biobank cohort. The exposure factor was baseline serum 25(OH)D concentrations. The associations were examined using Cox proportional hazards models, which were displayed as hazard ratios (HRs) with 95% confidence intervals (CIs).
Results: Over a median follow-up period of 10.92 years for cancer incidence outcomes, 12,137 new cancer cases were recorded. We observed that 25(OH)D concentrations were inversely related to the risk of colon, lung, and kidney cancer, and HRs (95% CI) for 25(OH)D ≥ 75.0 vs. < 25.0 nmol/L were 0.67 (0.45-0.98), 0.64 (0.45-0.91), and 0.54 (0.31-0.95), respectively. The fully adjusted model revealed a null correlation between 25(OH)D and the incidence of stomach, rectum, liver, pancreas, breast, ovary, bladder, brain, multiple myeloma, leukemia, non-Hodgkin lymphoma, esophagus, and corpus uteri cancer. Over a median follow-up period of 12.72 years for mortality outcomes, 8286 fatalities (including 3210 cancer mortalities) were documented. An "L-shaped" nonlinear dose-response correlation was detected between 25(OH)D and cancer/all-cause mortality; the respective HRs (95% CI) were 0.75 (0.64-0.89) and 0.65 (0.58-0.72).
Conclusion: These findings emphasize the importance of 25(OH)D in cancer prevention and longevity promotion among patients with MetS.
Keywords: 25-Hydroxyvitamin D; All-cause mortality; Cancer; Metabolic syndrome; Prevention.
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
References
-
- Saklayen MG (2018) The global epidemic of the metabolic syndrome. Curr Hypertens Rep 20(2):12. https://doi.org/10.1007/s11906-018-0812-z - DOI - PubMed - PMC
-
- Peiris CL, van Namen M, O’Donoghue G (2021) Education-based, lifestyle intervention programs with unsupervised exercise improve outcomes in adults with metabolic syndrome. A systematic review and meta-analysis. Rev Endocr Metab Disord 22(4):877–890. https://doi.org/10.1007/s11154-021-09644-2 - DOI - PubMed - PMC
-
- Maroufi NF, Pezeshgi P, Mortezania Z, Pourmohammad P, Eftekhari R, Moradzadeh M, Vahedian V, Nouri M (2020) Association between vitamin D deficiency and prevalence of metabolic syndrome in female population: a systematic review. Hormone Mole Biol Clin Investigat. https://doi.org/10.1515/hmbci-2020-0033 - DOI
-
- Prasad P, Kochhar A (2016) Interplay of vitamin D and metabolic syndrome: a review. Diabet Meta Synd 10(2):105–112. https://doi.org/10.1016/j.dsx.2015.02.014 - DOI
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical